Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride replenishes potassium stores; potassium is the major intracellular cation and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride supplies sodium and chloride ions to maintain electrolyte balance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Intravenous electrolyte replenishment,Maintenance of fluid and electrolyte balance,Prevention and treatment of hypokalemia,Caloric supplementation
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
IV infusion: 1 L contains 20 m Eq K+, 50 g dextrose, and 77 m Eq Na+ and Cl- each. Adjust rate based on potassium deficit and serum potassium. Typical adult rate: 10-20 m Eq/hour via peripheral IV, not to exceed 40 m Eq/hour or 200 m Eq/day.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Potassium: not applicable (homeostatic regulation); dextrose and sodium: endogenous, no elimination half-life. For exogenous potassium, distribution half-life ~1-1.5 h.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Potassium is primarily excreted renally; dextrose undergoes glycolysis and oxidative metabolism; sodium chloride is renally excreted.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal excretion: >90% of potassium is eliminated via kidneys; <10% fecal. Dextrose and sodium are primarily metabolized or renally excreted.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Potassium: essentially zero; dextrose: not bound; sodium: negligible binding.
Low protein binding; 0–11% bound, primarily to albumin.
Potassium: ~0.5 L/kg (body weight), representing total body water; sodium: ~0.2 L/kg (extracellular fluid); dextrose: ~0.2 L/kg (extracellular fluid).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%; oral: 100% (for potassium, if no malabsorption; dextrose and sodium fully absorbed).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR >50 m L/min: no adjustment. GFR 30-50: reduce rate by 50% or use with caution. GFR 10-29: avoid use or give with extreme caution, monitor ECG and serum K+. GFR <10: contraindicated.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution, monitor serum K+ closely. Child-Pugh C: contraindicated due to risk of hyperkalemia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
IV infusion: 0.5-1 m Eq/kg/dose, max 20 m Eq per dose, given over 1-2 hours. Alternatively, 0.1-0.2 m Eq/kg/hour. Max infusion rate: 0.5 m Eq/kg/hour. Dextrose concentration should be monitored to avoid hypoglycemia.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower infusion rates (10-15 m Eq/hour) due to reduced renal function. Monitor serum potassium and renal function frequently. Consider maximum daily dose of 100 m Eq.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
Concentrated potassium solutions (e.g., >40 m Eq/L) are for intravenous use only and must be diluted and administered slowly to avoid fatal hyperkalemia or cardiac arrest. Do not administer undiluted.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum potassium levels frequently; risk of hyperkalemia especially in renal impairment or with potassium-sparing diuretics.,Avoid rapid infusion to prevent hyperkalemia-induced cardiac arrhythmias.,Use with caution in patients with heart failure, severe renal insufficiency, or conditions predisposing to hyperkalemia.,Intravenous administration may cause phlebitis or extravasation injury.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Severe renal failure with oliguria or anuria,Addison's disease (untreated),Adynamia episodica hereditaria (hyperkalemic periodic paralysis),Concomitant use of potassium-sparing diuretics (e.g., spironolactone, amiloride),Acute dehydration or heat cramps
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and potassium-containing salt substitutes, as this may increase risk of hyperkalemia.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Potassium chloride and dextrose are pregnancy category C. No adequate studies in pregnant women. Potassium chloride at therapeutic doses is unlikely to cause fetal harm. Dextrose is a normal constituent of fetal blood. Sodium chloride at physiologic concentrations is safe. However, maternal electrolyte imbalances could affect fetal homeostasis. First trimester: Theoretical risk of teratogenicity from electrolyte disturbances but no evidence with IV infusion. Second/third trimester: Risk of neonatal hypoglycemia or electrolyte abnormalities if maternal levels are abnormal. Use only if clearly needed.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Potassium and chloride are normal milk constituents; dextrose is also present. Infusion of these substances at therapeutic levels does not increase milk concentrations significantly. No specific M/P ratio available; considered compatible with breastfeeding. However, monitor infant for gastrointestinal effects if high doses given.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy induces increased plasma volume and renal blood flow, potentially increasing clearance of electrolytes. However, dosing of potassium chloride and sodium chloride should be based on serum levels and clinical need, not standard adjustments. Volume expansion in pregnancy may require higher infusion rates to achieve desired electrolyte correction. Monitor serum levels closely to avoid under- or over-correction.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Use with caution in patients with renal impairment, heart failure, or adrenal insufficiency due to risk of hyperkalemia. Monitor serum potassium levels regularly during infusion. Avoid use in patients with hyperkalemia or severe metabolic acidosis. This solution is isotonic and provides maintenance electrolytes and calories; adjust rate based on fluid and electrolyte status. Incompatible with amphotericin B, cefepime, and sodium bicarbonate in solution.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Inform your healthcare provider if you have kidney problems, heart disease, or are taking potassium-sparing diuretics or ACE inhibitors.,Report any symptoms of high potassium such as muscle weakness, numbness, tingling, or irregular heartbeat.,This medication is given intravenously; do not adjust the infusion rate yourself.,Avoid potassium-containing salt substitutes or potassium supplements unless directed by your doctor.,Inform your provider if you are pregnant or breastfeeding.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride replenishes potassium stores; potassium is the major intracellular cation and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride supplies sodium and chloride ions to maintain electrolyte balance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: IV infusion: 1 L contains 20 m Eq K+, 50 g dextrose, and 77 m Eq Na+ and Cl- each. Adjust rate based on potassium deficit and serum potassium. Typical adult rate: 10-20 m Eq/hour via peripheral IV, not to exceed 40 m Eq/hour or 200 m Eq/day.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride and dextrose are pregnancy category C. No adequate studies in pregnant women. Potassium chloride at therapeutic doses is unlikely to cause fetal harm. Dextrose i. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.